573 related articles for article (PubMed ID: 25300859)
1. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.
Ohkuri T; Ghosh A; Kosaka A; Zhu J; Ikeura M; David M; Watkins SC; Sarkar SN; Okada H
Cancer Immunol Res; 2014 Dec; 2(12):1199-208. PubMed ID: 25300859
[TBL] [Abstract][Full Text] [Related]
2. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
[TBL] [Abstract][Full Text] [Related]
3. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
4. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.
Fujita M; Scheurer ME; Decker SA; McDonald HA; Kohanbash G; Kastenhuber ER; Kato H; Bondy ML; Ohlfest JR; Okada H
Clin Cancer Res; 2010 Jul; 16(13):3409-19. PubMed ID: 20472682
[TBL] [Abstract][Full Text] [Related]
5. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice.
Wang Z; Celis E
Cancer Immunol Immunother; 2015 Aug; 64(8):1057-66. PubMed ID: 25986168
[TBL] [Abstract][Full Text] [Related]
6. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses.
Huang L; Li L; Lemos H; Chandler PR; Pacholczyk G; Baban B; Barber GN; Hayakawa Y; McGaha TL; Ravishankar B; Munn DH; Mellor AL
J Immunol; 2013 Oct; 191(7):3509-13. PubMed ID: 23986532
[TBL] [Abstract][Full Text] [Related]
7. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
[TBL] [Abstract][Full Text] [Related]
8. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer.
Chandra D; Quispe-Tintaya W; Jahangir A; Asafu-Adjei D; Ramos I; Sintim HO; Zhou J; Hayakawa Y; Karaolis DK; Gravekamp C
Cancer Immunol Res; 2014 Sep; 2(9):901-10. PubMed ID: 24913717
[TBL] [Abstract][Full Text] [Related]
9. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
[TBL] [Abstract][Full Text] [Related]
11. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
Corrales L; Gajewski TF
Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
14. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
[TBL] [Abstract][Full Text] [Related]
15. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides.
Sauer JD; Sotelo-Troha K; von Moltke J; Monroe KM; Rae CS; Brubaker SW; Hyodo M; Hayakawa Y; Woodward JJ; Portnoy DA; Vance RE
Infect Immun; 2011 Feb; 79(2):688-94. PubMed ID: 21098106
[TBL] [Abstract][Full Text] [Related]
16. The GRA15 protein from
Wang P; Li S; Zhao Y; Zhang B; Li Y; Liu S; Du H; Cao L; Ou M; Ye X; Li P; Gao X; Wang P; Jing C; Shao F; Yang G; You F
J Biol Chem; 2019 Nov; 294(45):16494-16508. PubMed ID: 31416833
[No Abstract] [Full Text] [Related]
17.
Costa Franco MM; Marim F; Guimarães ES; Assis NRG; Cerqueira DM; Alves-Silva J; Harms J; Splitter G; Smith J; Kanneganti TD; de Queiroz NMGP; Gutman D; Barber GN; Oliveira SC
J Immunol; 2018 Jan; 200(2):607-622. PubMed ID: 29203515
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib promotes the efficacy of STING-targeted therapy by increasing antitumor CD8
Kosaka A; Yajima Y; Yasuda S; Komatsuda H; Nagato T; Oikawa K; Kobayashi H; Ohkuri T
Int J Cancer; 2023 Apr; 152(8):1685-1697. PubMed ID: 36495276
[TBL] [Abstract][Full Text] [Related]
19. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer.
Ni H; Zhang H; Li L; Huang H; Guo H; Zhang L; Li C; Xu JX; Nie CP; Li K; Zhang X; Xia X; Li J
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36126994
[TBL] [Abstract][Full Text] [Related]
20. MPYS/STING-mediated TNF-α, not type I IFN, is essential for the mucosal adjuvant activity of (3'-5')-cyclic-di-guanosine-monophosphate in vivo.
Blaauboer SM; Gabrielle VD; Jin L
J Immunol; 2014 Jan; 192(1):492-502. PubMed ID: 24307739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
